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CASE REPORT
WHIPPLE’S DISEASE: RARE DISORDER AND LATE DIAGNOSIS
Viviane Plasse RENON(1), Marcelo Campos APPEL-DA-SILVA(1), Rafael Bergesch D’INCAO(1), Rodrigo Mayer LUL(1),  
Luciana Schmidt KIRSCHNICK(2) & Bruno GALPERIM(1)
SUMMARY
Whipple’s disease is a rare systemic infectious disorder caused by the bacterium Tropheryma whipplei. We report the case of 
a 61-year-old male patient who presented to emergency room complaining of asthenia, arthralgia, anorexia, articular complaints 
intermittent diarrhea, and a 10-kg weight loss in one year. Laboratory tests showed the following results: Hb = 7.5 g/dL, albumin = 
2.5 mg/dL, weight = 50.3 kg (BMI 17.4 kg/m2). Upper gastrointestinal endoscopy revealed areas of focal enanthema in the duodenum. 
An endoscopic biopsy was suggestive of Whipple’s disease. Diagnosis was confirmed based on a positive serum polymerase chain 
reaction. Treatment was initiated with intravenous ceftriaxone followed by oral trimethoprim-sulfamethoxazole. After one year of 
treatment, the patient was asymptomatic, with Hb = 13.5 g/dL, serum albumin = 5.3 mg/dL, and weight = 70 kg (BMI 24.2 kg/m2). 
Whipple’s disease should be considered a differential diagnosis in patients with prolonged constitutional and/or gastrointestinal 
symptoms. Appropriate antibiotic treatment improves the quality of life of patients.
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INTRODUCTION
Whipple’s disease is a rare multisystemic infection caused by 
Tropheryma whipplei - a gram-positive bacterium belonging to the 
phylum Actinobacteria and a member of the order Actinomycetales5. 
It is recognized as an important bacterial cause of malabsorption, 
mostly affecting middle-aged Caucasian men. Its classic clinical course 
has three stages: (1) nonspecific prodromal symptoms, including 
migratory polyarthralgia (mainly in the large joints); (2) typical 
abdominal symptoms: pain, diarrhea, weakness, and weight loss; and 
(3) generalized stage, including steatorrhea, cachexia, lymphadenopathy, 
hyperpigmentation, and cardiovascular, pulmonary, and neurological 
dysfunctions11,14. Laboratory tests may provide several nonspecific 
findings that in combination can be suggestive of diagnoses such as: 
hypoalbuminemia, elevated erythrocyte sedimentation rate, and anemia8. 
Diagnosis is based on the presence of typical signs and symptoms 
and identification of Tropheryma whipplei in the histopathological 
examination of duodenal biopsies. When there is clinical suspicion 
without histological findings, the use of molecular biology tests is 
recommended, especially polymerase chain reaction (PCR)6. Treatment 
consists of induction of antibiotic therapy followed by a maintenance 
regimen for a prolonged period11.
CASE REPORT
Sixty-one-year-old Caucasian male patient admitted in March 2010 
to the emergency room for investigation of 10-kg weight loss, asthenia, 
anemia, and intermittent diarrhea, two to three bowel movements a day, 
without blood, mucus or pus for about one year. His previous medical history 
included 10 years of prodromal symptoms associated with depression and 
migratory arthralgia. During this period, the patient was seen by several 
physicians, who could not establish a diagnosis. At admission, the patient 
was thin, weighing 50.3 kg (BMI = 17.4 kg/m2), and presenting with lower 
limb edema and little ascites. Laboratory tests showed iron-deficiency 
anemia (Hb = 7.5 g/dL, ferritin = 111 ng/mL, transferrin saturation = 7.8%, 
serum iron = 14 ug/dL) and hypoalbuminemia (2.5 g/dL). In relation to 
the imaging studies, a chest X-ray revealed pericardial calcification and 
bilateral pleural effusion. An abdominal ultrasound showed hepatomegaly, 
distention of hepatic veins and inferior vena cava, and a small amount of 
free fluid in the abdominal cavity. A Doppler ultrasound demonstrated 
an ejection fraction of 40%, left ventricular contractile dysfunction, 
thickened aortic valve with moderate regurgitation and mild mitral valve 
regurgitation. Anti-HIV, HBsAg, anti-HCV, antinuclear antibodies, 
rheumatoid factor, and TSH were investigated and showed negative or 
within normal limit results. An upper gastrointestinal endoscopy showed 
focal enanthema of the duodenal mucosa. Biopsies were performed and 
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revealed spongy macrophages in the lamina propria using hematoxylin-
eosin staining and periodic acid-Schiff (PAS) staining. These findings 
are suggestive of Whipple’s disease (Fig. 1). Given the abnormal results 
described above, serum and CSF PCR were requested to investigate the 
presence of Tropheryma whipplei. Serum PCR was positive for Tropheryma 
whipplei, whereas CSF PCR was negative for this bacterium. Treatment 
was started with intravenous ceftriaxone 2 g/day for two weeks, followed 
by oral trimethoprim-sulfamethoxazole 800/160 mg twice daily for a 
period of 12 months. It is noteworthy that after 14 days of treatment, the 
patient had normalization of bowel habits and started to show progressive 
weight increase. 
After hospital discharge, the patient received outpatient follow-up for 
16 months. There was significant clinical and laboratory improvement 
after one year of treatment. At the last follow-up visit, five months after 
treatment completion, the patient remained asymptomatic, with albumin 
level of 5.3 g/dL, Hb level of 13.5 g/dL, and weighing 70 kg.
DISCUSSION
Whipple’s disease is a rare disorder. Its estimated annual prevalence is 
1:1,000,000, mostly affecting middle-aged Caucasian men5. Some studies 
have shown a higher prevalence among rural residents8,13. Tropheryma 
whipplei is found in the soil (which could explain a higher prevalence 
among farmers), in sewage contaminated water, in the oral cavity and 
feces of healthy individuals (although there is no evidence of interpersonal 
transmission)13. There is evidence that this organism may be ubiquitous in 
humans, since there are studies using PCR amplification of Tropheryma 
whipplei from samples of saliva, gastric juice, and duodenal biopsies of 
patients without Whipple’s disease5.
After infection, the bacterium invades the whole body, including the 
intestinal epithelium, lymphatic and capillary endothelium, synovium, 
heart, lungs, liver, brain, eyes, and skin. There is failure of immune 
response to Tropheryma whipplei in these sites, suggesting that such 
deficiency has a role in the occurrence of the disease8. Several immune 
system abnormalities have been associated with Whipple’s disease. 
These alterations may be transient during the exacerbation period or even 
typical of the host of the bacterium. Among the innate abnormalities, 
the association of Whipple’s disease with the human leukocyte antigen 
(HLA) has been described since 197915,24, when the association with HLA 
B27 was demonstrated even in the absence of ankylosing spondylitis15. 
Approximately 26% of patients have the HLA class I histocompatibility 
antigen and HLA B27 three to four times higher than expected, although 
this characteristic is not found in all populations studied8,9,13. Because of 
the low incidence of the disease, this association has been studied only 
in small case series, generating conflicting data1. 
This immune deficiency appears to be specific, because the patients 
are not predisposed to infection with other bacteria. In addition, IgG 
antibodies against Tropheryma whipplei are detected in approximately 
70% of healthy individuals. Whipple’s disease is rare, but apparently 
Tropheryma whipplei is not8. 
The classic disease can be divided into three stages: (1) nonspecific 
prodromal symptoms, mainly joint manifestations (e.g., arthritis, 
arthralgia, migratory polyarthralgia); (2) gastrointestinal symptoms such 
as diarrhea, weight loss, and weakness; and (3) generalized symptoms, 
including anemia, steatorrhea, hypoalbuminemia, and neurological and/
or cardiovascular manifestations11,14. The most frequent extra-intestinal 
manifestations are joint disease and constitutional symptoms (mainly 
weight loss, which is present in more than 2/3 of cases in some series). 
However, the following systems may also be affected in some way during 
the course of the disease in order of frequency: central nervous system 
(CNS), cardiovascular system, mucocutaneous system, pleuropulmonary 
system, and vision13. The mean time between the onset of prodromal 
symptoms and the advance stage is approximately six years8,10. However, 
despite this being the most common sequence, there are cases of isolated 
Whipple’s disease without gastrointestinal disorders5. Approximately 
15% of patients do not have typical symptoms and signs of the disease8,10. 
Fig. 1 - (A) Biopsy of the second portion of the duodenum, stained with periodic acid-Schiff (PAS), 10x magnification; and (B) stained with hematoxylin-eosin, 40x magnification, showing 
macrophages in the lamina propria.
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Therefore, the Whipple’s disease should be considered a differential 
diagnosis in many clinical situations: malabsorption with involvement 
of the small intestine (tropical sprue, celiac disease, sarcoidosis, and 
lymphoma), inflammatory rheumatic disease (seronegative arthritis), 
Addison’s disease, conjunctive tissue disease, and a variety of 
neurological diseases. Patients receiving immunosuppressive therapy, 
such as corticosteroids and tumor necrosis factor antagonists, may have 
a faster clinical progression of Whipple’s disease8. 
The central nervous system (CNS) may be affected in up to 50% of 
patients in combination with the gastrointestinal tract or even alone5,12,17. 
CNS manifestations are characterized by slowly progressive dementia, 
ophthalmoplegia, headache, myoclonus, hypothalamic dysfunction, and a 
pathognomonic movement - oculofacial-skeletal myorhythmia, dementia, 
ophthalmoplegia, and myoclonus are the most common1,17. Some of the 
most unusual symptoms are seizures and signs similar to ischemic brain 
syndrome2,22. Despite the intense gastrointestinal symptoms, our patient 
did not have any neurological manifestations or positive CSF PCR.
The most common gastrointestinal symptom of Whipple’s disease 
is weight loss, often associated with diarrhea. Abdominal pain, 
hepatosplenomegaly, and, occasionally, hepatitis may occur. Ascites has 
been reported in 5% of patients8. 
Joint involvement is the most common extra-intestinal symptom, 
occurring in approximately 65-90% of patients with classic disease, and 
it usually precedes gastrointestinal symptoms in up to 63% of affected 
individuals8,19. Intermittent migratory arthralgia and/or arthritis are the 
most common manifestations, usually in combination with polyarthritis, 
affecting the peripheral joints8,20.
Cardiac involvement is a common manifestation in Whipple’s disease 
and it is usually present with endocardial or valvular disease or, rarely, 
congestive heart failure13. After a long duration of nonspecific symptoms, 
our patient reached the generalized stage of the disease with uncommon 
manifestations such as pleural effusion, ascites, and heart failure.
In the present case report, the patient had clinical and laboratory 
manifestations consistent with Whipple’s disease, and the biopsy of 
the second portion of the duodenum showed typical findings, which 
confirmed the diagnosis.
Because of its broad spectrum of clinical manifestations, Whipple’s 
disease is very similar to other chronic inflammatory diseases5,8. This 
factor added to its low incidence in the general population makes 
the diagnosis difficult, usually leading to a late diagnosis. In the case 
described herein, our patient had prodromal symptoms for a period of 10 
years. His diagnosis was only established after the onset of the abdominal 
symptoms and the malabsorption syndrome.
Diagnosis is often made based on a biopsy of small intestine 
or proximal jejunum, as these regions are commonly affected in 
symptomatic patients, even in the early stage of the disease. The 
infiltration of the lamina propria of the small intestine by macrophages 
filled with bacilliform bodies, positive PAS, and diastase-resistant 
structures, accompanied by dilated lymphatic ducts, are specific and 
diagnostic aspects of Whipple’s disease5.
In some cases, the diagnosis is established without the presence of 
classic signs when typical histological lesions are found in duodenal 
biopsies stained with PAS10. Nevertheless, the presence of macrophages 
with positive PAS material is not completely specific for Whipple’s 
disease, since macrophages are also found in patients with infections 
caused by Mycobacterium avium-intracellulare, Rhodococcus equi, 
Bacillus cereus, Corynebacterium, Histoplasma, or certain types of 
fungi. Failure to obtain positive intestinal biopsies does not invalidate 
the diagnosis because the disease can be restricted to the submucosa and, 
therefore, it may not be diagnosed by a biopsy of the mucosa13.
Thus, the diagnosis should be made based on clinical and endoscopic 
suspicion, and confirmed by duodenal biopsy, associated with molecular 
biology methods (PCR), immunohistochemistry and serological 
methods5,24. PCR is an important diagnostic tool for this disease because 
it has high sensitivity and specificity and it is useful mainly in typical 
cases and/or when there is the possibility of histological confirmation 
of the diagnosis23. Nevertheless, PCR for Tropheryma whipplei in the 
serum is not a useful test for the diagnosis once a negative result does 
not exclude the diagnosis. On the other hand, false positive results in 
PCR can be seen in cases of intestinal colonization by T. whipplei. That’s 
why some authors recommend that the diagnosis should be established 
based on the combination of two positive tests, usually the histological 
analysis of duodenal biopsy with PAS staining, along with PCR or 
immunohistochemistry25. 
Electron microscopy has contributed in a decisive way, since 
1961, for the detection of the bacillus. Although electron microscopic 
examination is considered “gold standard” for confirmation of diagnosis8, 
it is a more expensive and demanding method since it involves complex 
laboratory procedures, which are not always available. Therefore, electron 
microscopy is only used to clarify those cases where PCR and/or histology 
provide doubtful results23. 
Immunohistochemistry is a tool that can help establish the diagnosis 
with good sensitivity8,23. This technique improves the histologic 
examination using T. whipplei-specific antibodies showing greater 
sensitivity than PAS staining, being able to identify T. whipplei using 
immunohistochemistry on tissues in which PAS staining provided 
negative results4,16.
When the diagnosis of Whipple’s disease is established, the 
cerebrospinal fluid should be tested with PCR, even in the absence 
of neurological signs, it has important implications for therapy and 
prognosis8,24. In patients with CNS involvement, CSF is usually normal 
or shows mild pleocytosis, while the PCR result is usually positive18,26.
Antibiotic therapy should be started early, preferred medications 
that have good penetration into the central nervous system, preventing 
neurologic relapses, given the frequent involvement of the CNS and the 
fact that this is the most frequent site of relapses5,8,9,23,24. If not treated, 
Whipple’s disease can have a fatal outcome5,8,11,24. Thus, the antibiotic 
selection was based on the fact that trimethoprim/sulfamethoxazole is 
an antibiotic that crosses the blood-brain barrier, with probability of 
being effective in the CNS involvement. Various antibiotic regimens 
have been tried, from chloramphenicol to tetracyclines, penicillin 
alone, penicillin and streptomycin, ampicillin, erythromycin, third 
generation cephalosporins5,8,23,24. Some studies suggest initial treatment 
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with penicillin and streptomycin intravenously for two weeks. Another 
possible regimen is ceftriaxone (2 g intravenous/day) during the first two 
weeks followed by oral administration of trimethoprim/sulfamethoxazole 
for one year5,8,24.
Whipple’s disease is an infectious disease with an excellent clinical 
response within a few weeks after initiation of antibiotic therapy5,8,23. 
The typical evolution of the treatment is the improvement of the classic 
symptoms (such as arthralgia and diarrhea) within two weeks after 
appropriate treatment is initiated. However, about 9-15%15 of patients 
develop failure during or relapse after treatment with trimethoprim-
sulfamethoxazole8. Jarisch-Herxheimer reaction has been reported 
after initiation of antibiotic therapy, with symptoms similar to systemic 
inflammatory response syndrome, especially in patients with CNS disease 
or receiving immunosuppressive therapy17.
According to different studies, the decision to discontinue therapy 
seems to depend on clinical and laboratory remission, as well as on 
decreased amount of PAS-positive macrophages and absence of free 
bacilli in follow-up biopsies after apparent clinical remission5,23. Also 
in relation to this fact, there are doubts related to the number of biopsies 
needed for a strict follow-up, as well as regarding the time interval 
between each procedure. Usually, if there is good clinical response, 
biopsy may be repeated six and twelve months after diagnosis, although 
some studies suggest longer time intervals5. 
Conversely, there is evidence that PAS-positive macrophages may 
remain in the lamina propria for several years after complete clinical 
remission, representing degraded bacterial material, which might cause 
a positive test result after treatment show a false positive result instead of 
a relapse5,23. Thus its validity in monitoring the disease is controversial. 
However, it has a 100% negative predictive value, meaning that the 
most important use of PCR seems to be to confirm the diagnosis after 
histology and exclude disease relapse after apparently effective therapy 
despite histological changes. Thus a negative PCR may exclude disease 
relapse (100% negative predictive value), whereas the visualization of 
intact bacilli by means of electron microscopy may be a sign of active 
disease5. In cases with neurological manifestations, antibiotic therapy 
should only be discontinued when the PCR is negative in the CSF and 
the duodenum23.
In addition, all patients should be monitored for life because relapses 
may occur after long-term remission with severe involvement of the 
CNS1,15.
Relapses of Whipple’s disease may appear several years after 
cessation of therapy, even when the initial treatment was considered 
effective. Even with an appropriate clinical treatment, there are reports 
of clinical relapse in about 2-33% of cases after a mean period of five 
years, and the CNS is the most frequent site involved8. It occurs most 
frequently in patients with CNS involvement and in patients treated with 
a single type of antibiotic or with antibiotics that do not cross the blood 
brain barrier (such as tetracycline or oral penicillin)1,23. 
In cases of failure or relapse, other antibiotic regimens are suggested. 
In patients without neurological involvement, doxycycline (100 mg twice 
a day) in combination with hydroxychloroquine (600 mg/day) without 
induction could be used. In patients with neurologic manifestations or 
positive CSF PCR, the regimen mentioned above may be associated 
with sulfadiazine7,24. 
RESUMO
Doença de Whipple: patologia rara e de diagnóstico tardio
Doença de Whipple é uma rara infecção sistêmica causada pelo 
Tropheryma whipplei. Caracteriza-se por fase prolongada de sintomas 
inespecíficos, levando longo período até o seu diagnóstico. Sem 
tratamento, pode ser grave e fatal, mas com antibioticoterapia tem ótima 
resposta clínica e laboratorial. Relatamos o caso de paciente masculino, 
61 anos, internado por astenia, anorexia, diarréia intermitente e perda 
de 10 kg em um ano. Apresentava-se com hemoglobina (Hb) 7,5 g/dL, 
albumina de 2,5 mg/dL, peso 50,3 kg (IMC 17,4). Endoscopia digestiva 
alta com áreas de enantema focal da mucosa duodenal e biópsia 
compatível com doença de Whipple. O diagnóstico foi confirmado com 
PCR sérica positiva, sendo instituído tratamento com ceftriaxone seguido 
de sulfametoxazol-trimetropim. Após um ano de tratamento, encontrava-
se assintomático, com Hb 13,5 g/dL, albumina sérica de 5,3 mg/dL e peso 
de 70 kg. Doença de Whipple deve fazer parte da lista de diagnósticos 
diferenciais em pacientes com sintomas constitucionais e/ou com queixas 
gastrointestinais com evolução prolongada. O tratamento antibiótico pode 
curar a infecção, recuperando a qualidade de vida do paciente.
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